5-HT2A receptor antagonists(Serotonin 2a (5-HT2a) receptor antagonists), DAT antagonists(Dopamine transporter antagonists), NET inhibitors(Norepinephrine transporter inhibitors)

Therapeutic Areas

Endocrinology and Metabolic Disease

Active Indication

ObesityOverweight

Inactive Indication

Diabetes Mellitus, Type 2

Originator Organization

Orexigen Therapeutics, Inc.

Active Organization

Nalpropion Pharmaceuticals, Inc.StartupOrexigen Therapeutics Ireland Ltd.Valeant Canada S.E.C./Valeant Canada LP

+ [1]

Inactive Organization

Orexigen Therapeutics, Inc.

Drug Highest PhaseApproved

First Approval Date

US (10 Sep 2014),

ObesityOverweight

Regulation-

Structure/Sequence

Molecular FormulaC33H41ClN2O5

InChIKeyKVNBDVQGENTICK-ITLPAZOVSA-N

CAS Registry1201668-08-7

Clinical Trials associated with Bupropion Hydrochloride/Naltrexone Hydrochloride

NCT06620562

/ Not yet recruitingPhase 4IIT

Improving Efficacity of Sleeve Gastrectomy With Naltrexone/Bupropion Extended-release Tablet - A Randomized Controlled Trial

The goal of this clinical trial is to assess the impact of combination therapy with Naltrexone-Bupropion (NB) in the post-operative period of sleeve gastrectomy (SG). on a) weight loss, b) resolution of comorbidities and c) eating behaviors.
Researchers will compare SG-NB group with SG-placebo group to see if they experience significantly higher excess weight loss (EWL) at 12 and 24 months and if there is a significantly higher percentage of patients with an EWL above 50% in the SG-NB group versus in the SG-placebo group.
Participants will be randomized 1:1 to SG in combination with NB versus SG with placebo. Patients will be started one month after surgery on a progressive dose of Naltrexone/Bupropion extended-release or placebo. Duration of therapy will be 24 months.Both groups will benefit from behavioral and nutritional support.

Start Date15 Oct 2024

Sponsor / Collaborator

Université Laval

[+1]

NCT06605703

/ RecruitingPhase 4

The Comparative Effectiveness of Step-down Treatment Options for Weight Management After Discontinuation of Semaglutide and Tirzepatide: a Randomized Controlled Trial (GLP1 Transition Trial)

The study compares the effectiveness of treatment options for weight management after discontinuing semaglutide and tirzepatide. The primary outcome is absolute and percentage weight change at 12-weeks.

Start Date18 Sep 2024

Sponsor / Collaborator

WW International, Inc.

NCT06098079

/ RecruitingPhase 4

A Phase IV Study to Assess the Effect of Naltrexone Hydrochloride Extended Release (ER) and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on the Occurrence of Major Adverse Cardiovascular Events

A randomized, double-blinded, placebo controlled study intended to capture cardiovascular outcomes during real-world use of naltrexone/bupropion (NB).

Start Date03 Jan 2024

Sponsor / Collaborator

Currax Pharmaceuticals LLCStartup

100 Clinical Results associated with Bupropion Hydrochloride/Naltrexone Hydrochloride

100 Translational Medicine associated with Bupropion Hydrochloride/Naltrexone Hydrochloride

100 Patents (Medical) associated with Bupropion Hydrochloride/Naltrexone Hydrochloride

133

Literatures (Medical) associated with Bupropion Hydrochloride/Naltrexone Hydrochloride

01 Feb 2025·ADDICTIVE BEHAVIORS

Exposure to Bupropion-SR vs. Placebo is associated with reductions in smoking among persons receiving methadone with no stated interest in smoking cessation

Article

Author: Dunn, Kelly E ; Umbricht, Annie ; Ware, Orrin D. ; Stitzer, Maxine L. ; Ware, Orrin D ; Stitzer, Maxine L ; Dunn, Kelly E.

Smoking is prevalent among individuals receiving methadone treatment. Reducing smoking among this population is needed as smoking is a leading cause of morbidity and preventable death. Smoking cessation interventions for persons receiving medication for opioid use disorder have yielded small changes in abstinence. Bupropion-SR was developed as an anti-depressant medication and is a first-line medication for smoking cessation. There is limited research on the effectiveness of bupropion-SR on smoking cessation among individuals receiving medication for opioid use disorder. This study is a secondary analysis of N = 72 adults enrolled in methadone treatment who endorsed smoking cigarettes. Participants were randomized to receive bupropion-SR 150 mg twice-daily (n = 35) or placebo (n = 37) in the primary study that examined bupropion-SR on cocaine use outcomes over a 30-weeks. Mixed model analyses examined secondary changes in self-reported cigarettes smoked, a self-reported measure of nicotine dependence, and quantitative urinary cotinine values. The longitudinal analysis of self-reported daily cigarettes identified no main effects of group and week however a significant interaction between group and week revealed that persons receiving bupropion-SR group reported less smoking early in the intervention. Longitudinal evaluation of changes in urinary cotinine revealed a significant main effect of week but no main effect of group or group x week interaction. Data suggest that bupropion-SR significantly decreased the number of self-reported cigarettes smoked relative to placebo and reduced nicotine dependence severity by the end of the study. Follow-up studies are needed as these decreases were not identified throughout the full study period or at termination.

01 Aug 2024·DIABETES OBESITY & METABOLISM

Total and H‐specific growth/differentiation factor 15 levels are unaffected by liraglutide or naltrexone/bupropion administration

Article

Author: Analitis, Antonis ; Stefanakis, Konstantinos ; Argyrakopoulou, Georgia ; Mantzoros, Christos S. ; Konstantinidou, Sofia K. ; Kokkinos, Alexander ; Simati, Stamatia

Abstract:

Aim:

To investigate growth/differentiation factor 15 (GDF‐15) levels in response to antiobesity medications, namely, liraglutide (Lira) and naltrexone/bupropion (N/B), in individuals with overweight or obesity.

Materials and Methods:

This was a prospective, non‐randomized clinical trial with a two‐arm, parallel design. A total of 42 individuals with overweight or obesity without type 1 or type 2 diabetes mellitus were enrolled. The participants received either Lira 3 mg or N/B 32/360 mg, along with diet and exercise, according to comorbidities, cost and method of administration. Participants underwent clinical and laboratory measurements at baseline, as well as at the 3‐ and 6‐month time points. Anthropometric measurements and body composition analysis via bioelectrical impendence analysis were performed. Total blood samples for GDF‐15 and H‐specific GDF‐15 were collected in the fasting state and every 30 min for 3 h after the consumption of a standardized mixed meal.

Results:

Overall, participants' weight was reduced by 9.29 ± 5.34 kg at Month 3 and 11.52 ± 7.52 kg at Month 6. Total and H‐specific GDF‐15 levels did not show significant changes during the mixed meal compared to values before the meal when all participants were examined at baseline, and at 3 and 6 month follow‐ups. No statistical significance was found when participants were examined by subgroup (Lira vs. N/B). No significant differences between treatment groups in postprandial area under the curve (AUC) or incremental AUC values were found at baseline or in the follow‐up months with regard to total and H‐specific GDF‐15 levels.

Conclusion:

Neither total nor H‐specific GDF‐15 levels are affected by Lira or N/B treatment in patients with overweight or obesity.

01 Feb 2024·Biochemical and biophysical research communications

Nanobodies as negative allosteric modulators for human calcium sensing receptor

Article

Author: Sun, Zengchao ; Geng, Yong ; Geng, Tengjie ; Xu, Hongxi ; Dai, Mei ; Dai, Yuanyuan ; Kou, Yongjun ; Zhang, Wenqing ; Xu, Jiaqiang ; Qiao, Huarui ; Lan, Zhongyun ; Han, Li ; Li, Lingyun ; Wang, Haonan ; Wang, Lu ; Chen, Xiaochen ; Cui, Qianqian

Human calcium sensing receptor (CaSR) senses calcium ion concentrations in vivo and is an important class of drug targets. Mutations in the receptor can lead to disorders of calcium homeostasis, including hypercalcemia and hypocalcemia. Here, 127 CaSR-targeted nanobodies were generated from camels, and four nanobodies with inhibitory function were further identified. Among these nanobodies, NB32 can effectively inhibit the mobilization of intracellular calcium ions (Ca²⁺_i) and suppress the G_12/13 and ERK_1/2 signaling pathways downstream of CaSR. Moreover, it enhanced the inhibitory effect of the calcilytics as a negative allosteric modulator (NAM). We determined the structure of complex and found NB32 bound to LB2 (Ligand-binding 2) domain of CaSR to prevent the interaction of LB2 domains of two protomers to stabilize the inactive state of CaSR.

News (Medical) associated with Bupropion Hydrochloride/Naltrexone Hydrochloride

16 Aug 2024

·www.prnewswire.com

Navamedic Q2 and H1 2024: Stable growth continues and is supported by a new licensing and supply agreement

OSLO, Norway, Aug. 16, 2024 /PRNewswire/ -- In first half of 2024, Navamedic ASA (OSE: NAVA) , a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, delivered revenues of NOK 277.2 million, up 12.8 per cent from the corresponding period last year. Adjusted EBITA amounted to NOK 41.1 million compared to NOK 26.3 million in 2023. The milestone payment of NOK 22.7 million following the agreement with Orion Corporation to market and sell Flexilev® and OraFID® in Europe is included. During the first six months of 2024, Navamedic has delivered on its strategy across the business. Following the launch of Eroxon® at the start of the year, the company renewed its contract with the Norwegian Hospital Procurement Trust, whereby Navamedic will continue to supply Norwegian hospitals with antibiotics until 2027. This agreement is expected to contribute more than 20 per cent revenue growth to the overall antibiotics' portfolio. In June, Navamedic signed a license and supply agreement with Orion Corporation (Orion) to market and sell Flexilev® and OraFID® in Europe. This agreement represents a major milestone in Navamedic's commercialisation strategy for Flexilev®. Orion has paved the way for Parkinson's disease treatment in Europe, making it a strong commercial partner for Navamedic. "Halfway into 2024, Navamedic can look back at an exciting first six months. There has been a lot of activity across the business, which has broadened Navamedic's geographical reach and product portfolio. Having been early to identify treatment areas with significant medical need and consumer demand, such as supplying antibiotics to hospitals and obesity, we have seen good growth across our key business areas: RX, Consumer and Hospital," said Kathrine Gamborg Andreassen, CEO of Navamedic ASA. Operating results (EBIT) for the first six months of 2024 amounted to NOK 33.8 million, compared to NOK 9.9 million in 2023. Operating costs ended at NOK 77.8 million, compared to NOK 74 million last year. Net financial items ended at negative NOK 9.7 million and profit before tax was NOK 24 million. Key figures and category update for the second quarter of 2024 Revenues for the second quarter amounted to NOK 156.3 million, up 26.2 per cent from last year. Adjusted EBITDA amounted to NOK 32.7 million, up from NOK 10.5 million in the second quarter of 2023. Gross margin for the quarter was 46.1 per cent, compared to 40.4 per cent in 2023. During the quarter, the company experienced steady growth across its three segments: Prescription Drugs (RX), Hospital and Consumer Health. As part of the Prescription Drugs (RX) category, sales of Mysimba® have remained stable in an increasingly competitive market. Imdur® and Forlax® have seen double digit growth year-over-year. Within the Hospital category, the antibiotics portfolio has delivered solid growth. The medical nutrition portfolio continues to deliver steady growth, delivering treatments for patients with Inborn Errors of Metabolism, which is considered a lifelong genetic disorder. In the Consumer Health category, Eroxon® was launched in Sweden in May, making it the first and only non-prescription treatment for erectile dysfunction in the country. It has also been a strong quarter for several hero products, including Absolut Torr and GeloRevoice, which are up 38 per cent and 35 per cent year-over-year, respectively. ThermaCare and Modifast continue to deliver stable sales. Navamedic plans to explore opportunities to expand both Absolut Torr and MedMade outside the Nordics Outlook Navamedic continues to see strong growth and new expansion opportunities and reiterates its mid-term ambition of building a NOK 1 billion revenue company. "We continue to build on a solid foundation and are exploring further opportunities for market expansion with our own products. A key driver for everyone at Navamedic is to be a proud contributor to public health, which includes identifying treatments and products that can enhance people's quality of life and ensuring that they are accessible, either through hospitals or pharmacies," Andreassen concluded. Presentation Navamedic will present the results for the second quarter and first half of 2024 at 08.30 today. CEO Kathrine Gamborg Andreassen and CFO Lars Hjarrand will host the presentation, which will take place at Haakon VIIs gate 2 in Oslo. It will be webcast at the following link: Note: EBITDA and other alternative performance measures (APMs) are defined and reconciled to the IFRS financial statements as a part of the APM section in the attached presentation. For further information, please contact: Kathrine Gamborg Andreassen, CEO, Navamedic Mobile: +47 951 78 680 E-mail: [email protected] Lars Hjarrand, CFO, Navamedic Mobile: +47 917 62 842 E-mail: [email protected] About Navamedic Navamedic ASA is a full-service provider of high-quality healthcare products to hospitals and pharmacies. Navamedic meets the specific medical needs of patients and consumers by leveraging its highly scalable market access platform, leading category competence and local knowledge. Navamedic is present in all the Nordic countries, the Baltics and Benelux, with sales representation in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (ticker: NAVA). For more information, please visit Navamedic.com. This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act. This information was brought to you by Cision The following files are available for download:

License out/inFinancial Statement

25 Jun 2024

·www.biospace.com

Arialys Therapeutics Appoints Peter Flynn, Ph.D., President and Chief Executive Officer

LA JOLLA, Calif.--(BUSINESS WIRE)-- Arialys Therapeutics, a biotechnology company pioneering new precision medicines for autoimmune neuropsychiatry, today announced the appointment of Peter Flynn, Ph.D., as President and Chief Executive Officer. Dr. Flynn has more than 20 years of executive leadership experience in the biotech industry, from private start-ups to established publicly traded companies, scaling companies through key financings and pharma partnerships, advancing novel therapeutics from scientific breakthrough to the clinic, and commercializing FDA-approved medicines. In conjunction, Jay Lichter, Ph.D., Managing Partner of Avalon BioVentures and former President and CEO of Arialys, has been appointed Chair of the company’s Board of Directors. Dr. Lichter said, “Peter’s success in thoughtfully building and funding companies and experience advancing novel therapeutics in the clinic will be invaluable as Arialys brings its lead drug candidate, ART5803, into clinical study for the treatment of ANRE and autoimmune psychosis. As Chair, I look forward to working with Peter and the rest of the team to develop novel precision medicines and diagnostics to help millions of people who suffer from neuropsychiatric disorders driven by autoimmune disease.” “Arialys is on the forefront of transforming the treatment landscape for neuropsychiatry by applying a precision medicine approach to breakthrough insights in autoimmune driven neuropsychiatric diseases,” said Dr. Flynn. “Arialys has already generated significant preclinical proof-of-concept data for ART5803, and I look forward to working with the dedicated team and distinguished Clinical Advisory Board to advance this potentially transformative medicine into the clinic next year. I also am excited to build upon the team’s insights, discovering and characterizing pathogenic autoantibodies, to explore additional therapeutic opportunities for the treatment of CNS diseases driven by autoimmunity.” Prior to joining Arialys, Dr. Flynn was Cofounder and Chief Operating Officer of Artiva Biotherapeutics, where he oversaw business development and strategy, research, manufacturing, and corporate operations. During his time at Artiva, the company achieved significant financing, clearance of several IND applications, the establishment of a built-to-fit office, research labs, and internal GMP manufacturing capability, and corporate partnerships with Merck and Affimed. Prior to Artiva, Dr. Flynn was the Global Head of Development and a senior executive at Orexigen, where he oversaw the post-marketing development and regulatory aspects of Contrave®, an FDA-approved weight-loss prescription medication. Coordinating staff across the U.S., E.U., and MENA regions, he collaborated with the commercial team to ensure effective medical and regulatory support for global partnerships and direct-to-consumer and telemedicine campaigns for Contrave. Prior to Orexigen, Dr. Flynn was Senior Vice President, Early Program Development at Fate Therapeutics, where he was responsible for the development of the iPSC platform and was a member of the senior executive team for Fate’s IPO in 2013. Prior to Fate, he was Vice President of Research at Ren Pharmaceuticals. Dr. Flynn started his industry career at the antibody therapeutics company KaloBios, where as head of biochemistry he helped build both the platform technology and therapeutic pipeline. Dr. Flynn received a Ph.D. in biochemistry from the Imperial Cancer Research Fund / University College London and was a postdoctoral fellow at the University of California, San Francisco. About ANRE and ART5803 Anti-NMDA receptor encephalitis (ANRE), one of the most common forms of autoimmune encephalitis, is a rare, potentially lethal, and poorly managed neurological disease because it is often misdiagnosed. ANRE is caused by autoantibodies that crosslink and drive internalization of NMDA receptors (NMDAR), resulting in psychosis. Arialys’ lead therapeutic ART5803 is a therapeutic antibody designed to treat ANRE by blocking NMDAR autoantibodies. Arialys has generated promising preclinical data in a nonhuman primate disease model confirming ART5803 reverses encephalitis and decreases the behavioral symptoms caused by NMDAR autoantibody pathogenicity in the brain. Arialys has received orphan drug designation from the U.S. FDA for ART5803 for the treatment of ANRE. About Arialys Therapeutics Founded to explore the latest discoveries in autoimmune neuropsychiatry, Arialys Therapeutics is developing new precision medicines to specifically block pathogenic autoantibodies in the brain and meaningfully expand the treatment possibilities for neuropsychiatric disorders driven by autoimmune disease. Arialys is headquartered in the Avalon BioVentures Accelerator on the Torrey Pines Mesa, in La Jolla, California. For more info, visit .

Executive ChangeOrphan DrugINDIPO

17 Apr 2024

·www.biospace.com

Xeno Biosciences Announces New CEO and Financing - April 17, 2024

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Xeno Biosciences Inc., a clinical stage drug discovery and development company advancing therapeutics for the treatment of obesity and metabolic diseases, announced today a change in executive leadership as of September 2023, and the completion of an additional financing round in February of 2024. This financing of $1.15M will fund a Phase 1b trial of the company’s lead compound, Xen-101, in obese individuals. The trial is expected to have top line results by the end of the year. The new president and CEO, Dennis D. Kim, MD, MBA, has 25 years of obesity and metabolic drug development expertise experience and has brought multiple obesity and metabolic disease drugs to the clinic and to market, including Byetta® (exenatide), Symlin® (pramlintide), Contrave® (bupropion/naltrexone), and seladelpar. He has been involved in numerous IPO’s/secondary offerings and has been the chief medical officer of multiple public companies, most recently at CymaBay Therapeutics, where he oversaw the design and execution of seladelpar Phase 3 Pivotal Program. “I’m excited to be spearheading the development of Xeno’s new oral obesity drug which has been shown to have high tolerability in initial Phase I trial and has a novel mechanism of action.” said Dr. Dennis Kim. “I have dedicated my career to this area of science and medicine. After many years of development, I am truly gratified to see obesity pharmaceuticals as having the potential to impact the lives of billions of people around the world. There is a strong unmet need for a drug with the pro Xen-101 and I look forward to our Phase 1b clinical trial results in obese adults in the near future.” “Dennis has an extraordinary depth of knowledge and is highly respected in the obesity field; I could not imagine anyone more perfect to lead our company,” said Jeff Arnold, Chairman and a Director at Xeno since 2017. “We are delighted that he has decided to join us and lead this exciting project.” For more information about Xeno Biosciences please contact Dr. Dennis Kim at dk23@xenobiosciences.com. About Xeno Biosciences Inc. Xeno Biosciences Inc. is a privately held drug development company dedicated to finding safe and effective treatments for obesity and metabolic diseases. Xeno is advancing its lead development candidate, XEN-101, to address the unmet need for an effective, well-tolerated, orally administered obesity treatment. With a new understanding of the underlying mechanism of action of Roux-en-Y Gastric Bypass Surgery (RYGB), Xeno has developed a substitute for gastric bypass in a daily oral pill. XEN-101 has been shown to have wide safety margins and high tolerability in initial clinical trials. Dennis D. Kim, MD, MBA Dr. Dennis Kim is a scientist and a physician executive who brings 25 years of clinical research and biopharmaceutical industry experience to Xeno Biosciences. Dr. Kim served in a variety of senior executive positions in the industry, most recently as Chief Medical Officer at CymaBay, Emerald Biosciences, and Zafgen, Inc., as well as at Orexigen Therapeutics as the Senior Vice President of Medical Affairs. He also held various senior management positions at Amylin Pharmaceuticals, Inc. for over 7 years, including Executive Director of Corporate Strategy and Program Medical Lead for the development and commercialization of Byetta® (exenatide) for the treatment of type 2 diabetes. Dr. Kim completed his fellowship in Endocrinology/Metabolism at the University of California, San Diego (UCSD) School of Medicine during which time he investigated the pathophysiology of diabetes and metabolic syndrome. He is extensively published in top peer-reviewed medical and scientific journals with over 50 publications to his name. Dr. Kim also received an MBA degree with honors from UCSD Rady School of Management with an emphasis on biotech structure and strategy. The securities sold in the aforementioned private placement have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States in the absence of an effective registration statement or an applicable exemption from the registration requirements of the Securities Act. This press release shall not constitute an offer to sell or the solicitation of an offer to buy the aforementioned shares. In addition, this press release contains certain forward-looking statements regarding, among other things, statements relating to goals, plans and projections regarding the company’s financial position, results of operations, market position, product development and business strategy. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statements can be guaranteed and actual results may differ materially from such statements. The information in this release is provided only as of the date of this release, and the company undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law. View source version on businesswire.com: Contacts Dr. Dennis Kim dk23@xenobiosciences.com Source: Xeno Biosciences Inc. View this news release online at:

Executive ChangePhase 1Phase 2

100 Deals associated with Bupropion Hydrochloride/Naltrexone Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
-	Bupropion Hydrochloride/Naltrexone Hydrochloride	A08AA62	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Obesity	US	Nalpropion Pharmaceuticals, Inc.Startup	10 Sep 2014
Overweight	US	Nalpropion Pharmaceuticals, Inc.Startup	10 Sep 2014

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	Phase 3	US	Orexigen Therapeutics, Inc.	01 May 2007

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04531176 (EMPOWER-T2D, CTgov)	Phase 4	Diabetes Mellitus, Type 2 \| Obesity	74	Weight Management Program (WMP)+Orlistat+liraglutide 3.0 mg+Phentermine / Topiramate Extended Release Oral Capsule+naltrexone/bupropion extended-release (Obesity-centric Approach + AOM)	fsiclgwrcn(gxyjrobrmr) = ygbrgrtccn fobjjvsdfo (edxarfzwlz, xqmggdfcwm - rjzqyfshrf) View more	-	22 Jul 2024
				Weight Management Program (WMP) (Obesity-centric Approach Without AOM)	fsiclgwrcn(gxyjrobrmr) = klrhdguyph fobjjvsdfo (edxarfzwlz, ojfhlzgcfk - xhtwtpcegi) View more
NCT04662801 (CTgov)	Phase 2/3	Overweight \| Weight Gain	26	Behavioral Weight Loss (BWL) (Behavioral Weight Loss)	omqysmruks(anrkmgwvhc) = wotzozwdeo hsheqeiduq (lwfhaqlepp, zvraxngcry - tdbcyydgqx) View more	-	13 Nov 2023
				Behavioral Weight Loss (BWL)+medication added (Behavioral Weight Loss + Medication)	omqysmruks(anrkmgwvhc) = ddrgxyeijo hsheqeiduq (lwfhaqlepp, fymyugdvkn - fosmaebbyq) View more
ANA2023	Not Applicable	-	211	GLP-1 agonists	lnsirfqbip(iymxcpxtkt) = ukslhnofvp mvajydflhw (nrgbubalzz ) View more	Positive	01 Sep 2023
				Other weight loss medications	lnsirfqbip(iymxcpxtkt) = nzuijgnjwl mvajydflhw (nrgbubalzz ) View more
NCT03539900 (CTgov)	Phase 2/3	Binge-Eating Disorder	89	Bupropion Hydrochloride, Naltrexone Hydrochoride Drug Combination (NB Medication)	qwpcqgdpxw(vvupeotdte) = xesvuzgwdr xqgmdvmjsf (phecmjbmys, zwcilrvbzc - hzsxyomnym) View more	-	24 Jul 2023
				Placebo (Placebo)	qwpcqgdpxw(vvupeotdte) = kbueluxomd xqgmdvmjsf (phecmjbmys, lemndbtfdn - wsedlfdrua) View more
NCT03374956 (CTgov)	Phase 3	Obesity	193	liraglutide+Phentermine-Topiramate+Naltrexone/bupropion (Intervention Group)	kbloheutsg(tspgwprwrg) = uucpqnogrf axjbtpmrrh (soruvkwhyf, ogyjbqhwao - xbuuwzwxko) View more	-	18 Jul 2023
				liraglutide+Phentermine+Naltrexone/bupropion (Control Group)	kbloheutsg(tspgwprwrg) = hecoejnozp axjbtpmrrh (soruvkwhyf, kvktrpumdi - xccmzqrtds) View more
NCT03063606 (CTgov)	Phase 2/3	Binge-Eating Disorder \| Obesity	31	bupropion+placebo+Naltrexone (Cognitive-Behavioral Therapy (CBT) Plus On-going Blinded Pharmacotherapy)	sleurielfw(aomvvtpwur) = xtzkjglcwo volpeexkqm (jypcgiqptn, gtltswtwle - nhufbpljlj) View more	-	07 Jul 2023
				bupropion+placebo+Naltrexone (On-going Blinded Pharmacotherapy)	sleurielfw(aomvvtpwur) = lrfuxczhoo volpeexkqm (jypcgiqptn, yuunpxfjjo - momreeixld) View more
NAASO2022	Not Applicable	Overweight \| Obesity	227	Naltrexone-Bupropion	ygswmjdnqn(qijvtcevpn) = Four expected non-serious adverse events were reported pdhbtddlhz (qrwwzffqep )	Positive	21 Nov 2022
COR-I (NAASO2020)	Not Applicable	-	86	Naltrexone/Bupropion 16 mg	emdffgpdzz(zydinxygow) = lepevmbpcz odmyydmfid (pitusalxbv ) View more	-	04 Nov 2020
				Naltrexone/Bupropion 32 mg	emdffgpdzz(zydinxygow) = vlvzuvbxze odmyydmfid (pitusalxbv ) View more
NCT00456521 (COR-BMOD, NAASO2020)	Phase 3	Overweight \| Obesity	1,739	Naltrexone sustained-release (SR) /bupropion SR (NB)	dreugtnbjz(lzpyybzbjz) = lvldolairq kbnrnoiqhn (ygfaraklhj ) View more	Positive	04 Nov 2020
				Placebo	dreugtnbjz(lzpyybzbjz) = fmbhaexsgr kbnrnoiqhn (ygfaraklhj ) View more
LIGHT trial (NAASO2020)	Phase 3	Overweight \| Obesity	1,853	Naltrexone/Bupropion	kfisivrpaz(yoofsyqgvw) = afjzfxecca ktninoojft (rryvnhbuuc ) View more	-	04 Nov 2020
				Placebo	kfisivrpaz(yoofsyqgvw) = ohpwpknmrq ktninoojft (rryvnhbuuc ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis